Arrowhead Research | ARWR - Operating Profit


Arrowhead Research reported $40.81M in Operating Profit for its fiscal quarter ending in December of 2025.





Operating Profit Change Date
Agios Pharmaceuticals USD -121.58M 4.71M Dec/2025
Alnylam Pharmaceuticals USD 29.4M 59.36M Dec/2025
Anika Therapeutics USD -4.28M 32.1M Mar/2025
Arrowhead Research USD 40.81M 3.3M Dec/2025
Heron Therapeutics USD -5.66M 782K Sep/2024
Incyte USD 383.88M 47.43M Dec/2025
Ionis Pharmaceuticals USD -160.18M 300.02M Sep/2025
Ligand Pharmaceuticals USD 158.89M 149.17M Sep/2025
Merck USD 6.24B 318M Dec/2025
Moderna USD -857M 597M Dec/2025
Nektar Therapeutics USD -34.34M 15.43M Sep/2024
Novartis USD 4.5B 363M Sep/2025
Sarepta Therapeutics USD -62.88M 178.46M Sep/2025
TG Therapeutics USD 29.36M 5.48M Sep/2025
Ultragenyx Pharmaceutical USD -114M 56.89M Dec/2025
Vertex Pharmaceuticals USD 1.26B 24.5M Dec/2025
Xencor USD -47.52M 14.35M Sep/2025